See every side of every news story
Published loading...Updated

Why Is STAAR Surgical Stock Skyrocketing Tuesday? - Staar Surgical (NASDAQ:STAA), Alcon (NYSE:ALC)

SWITZERLAND AND CALIFORNIA, AUG 5 – Alcon will pay a 59% premium to acquire STAAR Surgical for $1.5 billion to expand its implantable lens offerings amid rising global myopia rates.

  • On August 5, 2025, STAAR Surgical agreed to be acquired by Alcon for $28 per share in cash, valuing the deal at about $1.5 billion.
  • The sale follows STAAR's financial challenges and fluctuating demand in China, with shareholder approval still required and a fairness investigation underway.
  • Alcon expects the acquisition to strengthen its surgical vision correction offerings, especially for patients unsuitable for other surgeries like LASIK, amid rising severe myopia globally.
  • The $28 per share price represents a roughly 59% premium to STAAR's recent average, and analysts note this deal bolsters Alcon’s market position despite STAAR’s setbacks in China.
  • The transaction is expected to close within six to twelve months, become accretive to Alcon's earnings by year two, and expand treatment options across the myopia spectrum.
Insights by Ground AI
Does this summary seem wrong?

15 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 86% of the sources are Center
86% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Bloomberg broke the news in United States on Tuesday, August 5, 2025.
Sources are mostly out of (0)

Similar News Topics